• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 497648 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414228605 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414228605 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Vanda Pharmaceuticals Trading Higher on 1.6x Above-Average Volume (VNDA)

Published on Fri, 05/10/2013 - 13:15
By Peter Chu

Vanda Pharmaceuticals's stock is up 1.6% to $5.14 on heavy trading volume. Today's volume of 371,000 shares tops the average 30-day volume of 232,000 shares. Spikes in volume can validate a breakout or signify a potential turning point.

Vanda Pharmaceuticals share prices have moved between a 52-week high of $5.17 and a 52-week low of $2.92 and are now trading 76% above that low price at $5.14 per share. The 200-day and 50-day moving averages have moved 0.23% higher and 2.04% higher over the past week, respectively.

Potential upside of 65.4% exists for Vanda Pharmaceuticals, based on a current level of $5.14 and analysts' average consensus price target of $8.50. The stock should find initial support at its 50-day moving average (MA) of $4.23 and further support at its 200-day MA of $3.96.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of clinical-stage, small molecule product candidates for central nervous system disorders.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Shares of Travelers Rise Above Previous ...

Shares of Travelers (NYSE:TRV) traded today at $97.70, breaking its 52-week high. Appr ...

Shares of Transglobe Energy Fall to a Ne...

Transglobe Energy (NASDAQ:TGA) traded today at a new 52-week low of $4.66. So far toda ...

Shares of Teleflex Have Risen Above Prev...

Shares of Teleflex (NYSE:TFX) traded today at $111.56, breaking its 52-week high. Appr ...

Southwest Gas: 52-Week High Recently Ecl...

Southwest Gas (NYSE:SWX) traded today at a new 52-week high of $56.15. So far today ap ...

Shares of Southwestern Energy Have Falle...

Shares of Southwestern Energy (NYSE:SWN) traded at a new 52-week low today of $31.28. ...

Shares of Sovran Self Storage Rise to a ...

Shares of Sovran Self Storage (NYSE:SSS) traded today at $82.98, breaking its 52-week h ...

Recent 52-Week High Exceeded in Shares o...

Sonic (NASDAQ:SONC) traded at a new 52-week high today of $24.92. So far today approxi ...

Super Micro Computer: The Winning Streak...

Super Micro Computer (NASDAQ:SMCI) traded today at a new 52-week high of $31.00. This ...